Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunesuppression: First-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients

Transplantation

Volumn 66, Issue 1, 1998, Pages 44-49

  Zanker, Bernd ^a   Schneeberger, Helmut ^a   Rothenpieler, Uwe ^a   Hillebrand, Gunther ^a   Illner, Wolf Dieter ^a   Theodorakis, Ioannis ^a   Stangl, Manfred ^a   Land, Walter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETREATMENT;

EID: 0032528256     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199807150-00007     Document Type: Article

References (22)

1. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Transplantation 1997; 63: 664.
2. Ader JL, Tack I, Lloveras JJ, et al. Renal functional reserve in cyclosporin-treated recipients of kidney transplant. Kidney Int 1994; 46: 1657.
3. Nunley JR, King A, Comstock T, Posmer M, Marshall C, Sica DA. Cyclosporine's effect on functional reserve in the renal allograft. Transplantation 1991; 51: 190.
4. McCauly J. The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 1993; 2: 662.
5. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
6. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 1990; 4: 554.
7. Mihatsch MJ, Thiel G, Ryffel B. Morphologic diagnosis of cyclosporine nephrotoxicity. Semin Diagn Pathol 1988; 5: 104.
8. Bertani T, Ferrazzi P, Schieppati A. Nature and extent of glomerular injury induced by cyclosporine in heart transplant recipients. Kidney Int 1991; 40: 243.
9. Colvin RB. The renal allograft biopsy. Kidney Int 1996; 50: 1069.
10. Solez K, Axelsen RA, Benediktsson H. International standardization of nomenclature and criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
11. Miller RA. The aging immune system: primer and prospectus. Science 1996; 273: 70.
12. Ismail H, Hakim RM, Helderman JH. Renal replacement therapies in the elderly: Part II. Renal transplantation. Am J Kidney Dis 1994; 23: 1.
13. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448.
14. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 1992; 232: 194.
15. Kaplan C, Pasternack B, Shah H, Gallo G. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975; 80: 227.
16. Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318 1499.
17. Sutherland F, Burgess E, Klassen J, Buckle S, Paul LC. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transpl Int 1993; 6: 129.
18. Hollander AAMJ, van Saase JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610.
19. European Mycophenolate Mofetil Co-operative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
20. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
21. Van Gelder T, Klaassen RJL, van Riemsdijk-van Overbeeke IC, Ijzermans JNM, Weimar W. Mycophenolate mofetil and prednisone as maintenance treatment after kidney transplantation. Transplantation 1997; 63: 1530.
22. European Tacrolimus Multicenter Renal Study Group. Multicenter randomized trial comparing tacrolimus and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436.